Jing Zhao
Denver
Education
Ph.D., biology, Baylor College of Medicine; M.S., biostatistics, Harvard T.H. Chan School of Public Health; B.S., biological science and biotechnology, Tsinghua University, China
Summary of Experience
Dr. Zhao draws on her background in biology and biostatistics in her research on the value of health care products and her work on analytics across the product life cycle. She has broad experience with the development and implementation of health economics and outcomes research (HEOR) strategies in a number of therapeutic areas, including diabetes, oncology, immunology, infectious diseases, and hematology. Dr. Zhao applies advanced research methods for health care data to real-world evidence development, individualized medicine, predictive analytics, and cost-effectiveness analysis. Her work has been used to inform health care regulators and payers in US and global markets, published in peer-reviewed journals, and presented at clinical and economic research conferences.
Selected Publishing
-
Network meta-analysis of nivolumab plus ipilimumab in the second-line setting for advanced hepatocellular carcinoma
Journal of Comparative Effectiveness Research, 2021
2021Parikh ND, Marshall A, Betts KA, Song J, Zhao J, Yuan M, Wu A, Huff KD, Kim R
-
Comparative safety and benefit-risk profile of biologics and oral treatment for moderate-to-severe plaque psoriasis: A network meta-analysis of clinical trial data
Journal of the American Academy of Dermatology, 2021
2021Shear NH, Betts KA, Soliman AM, Joshi A, Wang Y, Zhao J, Gisondi P, Sinvhal R, Armstrong AW
-
Five-year Estimated Glomerular Filtration Rate in Patients With Hypoparathyroidism Treated With and Without rhPTH(1-84)
The Journal of Clinical Endocrinology and Metabolism, 2020
2020Chen KS, Gosmanova EO, Curhan GC, Ketteler M, Rubin M, Swallow E, Zhao J, Wang J, Sherry N, Krasner A, Bilezikian JP
-
Prevalence of chronic respiratory morbidity, length of stay, inpatient readmissions, and costs among extremely preterm infants with bronchopulmonary dysplasia
Expert Review of Pharmacoeconomics & Outcomes Research, 2020
2020Mowitz ME, Mangili A, Han L, Ayyagari R, Gao W, Wang J, Zhao J, Sarda SP
-
Matching-adjusted Indirect Comparisons of the Efficacy and Safety of Acalabrutinib Versus Other Targeted Therapies in Relapsed/Refractory Mantle Cell Lymphoma
Clinical Therapeutics, 2019
2019Telford C, Kabadi SM, Abhyankar S, Song J, Signorovitch J, Zhao J, Yao Z
-
Real-World Effectiveness and Tolerability of Pazopanib as First Targeted Therapy in Metastatic Renal Cell Carcinoma: A Retrospective Chart Review in Latin America
Advances in Therapy, 2019
2019Muniz DQ, Ratto B, Yang H, Zhao J, Jenkins M, Signorovitch J, Dezzani L, Salman P, Medina ML, Lopera D, Lerzo G, Del Castillo C, Chacon M, Martin A, Campos-Gomez S
-
Health Care Burden of Bronchopulmonary Dysplasia Among Extremely Preterm Infants
Frontiers in Pediatrics, 2019
2019Mowitz ME, Ayyagari R, Gao W, Zhao J, Mangili A, Sarda SP
-
Identifying a subpopulation with higher likelihoods of early response to treatment in a heterogeneous rare disease: a post hoc study of response to teduglutide for short bowel syndrome
Therapeutics and Clinical Risk Management. 2018 Jul 25;14:1267-1277
2018Chen KS, Xie J, Tang W, Zhao J, Jeppesen PB, Signorovitch JE
-
Is time to progression associated with post-progression survival in previously treated metastatic non-small cell lung cancer with BRAF V600E mutation? A secondary analysis of phase II clinical trial data
BMJ Open. 2018 Aug 17;8(8):e021642
2018Li J, Sasane M, Zhang J, Zhao J, Ricculli ML, Yao Z, Redhu S, Signorovitch J
-
Comparative Efficacy of Treatments for Previously Treated Advanced or Metastatic Non-Small-Cell Lung Cancer: A Network Meta-Analysis
Advances in Therapy. 2018 Jul;35(7):1035-1048
2018Li J, Sasane M, Zhao J, García-Horton V, Zhang P, Ricculli ML, Zhou ZY, Signorovitch J
-
Healthcare Resource Use, Costs, and Disease Progression Associated with Diabetic Nephropathy in Adults with Type 2 Diabetes: A Retrospective Observational Study
Diabetes Therapy. Jun 2017;8(3):555-571
2017Zhou Z, Chaudhari P, Yang H, Fang AP, Zhao J, Law EH, Wu EQ, Jiang R, Seifeldin R
-
A Risk Score for Fluconazole Failure among Patients with Candidemia
Antimicrobial Agents Chemotherapy. 2017 Apr 24;61(5). pii: e02091-16. doi: 10.1128/AAC.02091-16. Print 2017 May.
2017Yang H, Ostrosky-Zeichner L, Harrington R, Azie N, Li N, Zhao J, Koo V, Wu EQ
News
-
October 15, 2021